HCV clearance by direct-acting antiviral treatments reverses insulin resistance in chronic hepatitis C patients

2017 Journal of gastroenterology and hepatology In Press;

BACKGROUND AND AIM: Chronic hepatitis C (HCV), particularly genotype 1, is associated with insulin resistance (IR) and diabetes. We evaluated the impact of HCV clearance by all-oral direct-acting antiviral (DAAs) treatments on IR and glycemic control. METHODS: Included in this prospective case-control study were 133 consecutive HCV-genotype 1 patients with advance liver fibrosis (F3-F4) without type 2 diabetes. Sixty-eight treated with DAAs and 65 untreated. Liver fibrosis was assessed by transient elastography. Pre-, end- and 3 months post-treatment withdrawal IR homeostasis was assessed by HOMA-IR, QUICKI and HOMA-B. RESULTS: At baseline, treated and untreated patients showed similar liver fibrosis levels, HOMA-IR was 4.90+/-4.62 and 4.64+/-5.62, respectively. HOMA-IR correlated with HCV RNA levels. At the end of treatment, all patients cleared HCV RNA, regardless of liver fibrosis and BMI, a reduction in HOMA-IR at 2.42+/-1.85 was showed (p

Pubmed : 29228501